Alzheon, Inc. announced that it has appointed Menghis Bairu, MD, Franklin Berger and Scott Minick to the company's Board of Directors. Each of these new Board members brings more than 25 years of strategic and management experience in the biotechnology industry as well as unique Alzheimer's drug development expertise to support Alzheon's growth as a leading Alzheimer's company. The three newly-appointed Board members join Martin Tolar on Alzheon's Board of Directors.

Menghis Bairu, MD, has been the Chief Medical Officer, Executive Vice President and Head of Global Development of Elan Corporation Plc. since October 2008. Franklin Berger, CFA, is a biotechnology industry analyst with more than 25 years of experience in capital markets and financial analysis.

He serves as a consultant to pharmaceutical and biotechnology companies, asset managers and venture capital firms. Scott Minick is President and Chief Executive Officer of BIND Therapeutics.